FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
You may also be interested in...
US FDA and CMS explore reimbursement ideas to strengthen business case for antimicrobial development; new approval pathway likely is only needed in special situations.
US FDA draft guidance on Limited Population Antibacterial Drug pathway says eligibility considerations for preventative products will center on size of population receiving drug, not incidence of infection.
US FDA Commissioner outlines licensing fee reimbursement arrangement intended to provide better financial incentives for development.